A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis | MicrobiomeTrials← Back to trialsNCT07845487
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-28Est. Completion: 2027-10
Enrollment target: 204 participants Locations- Site US-022, Sun City, Arizona, United States
- Site US-018, San Diego, California, United States
- Site US-028, Bristol, Connecticut, United States
- Site US-026, Orlando, Florida, United States
- Site US-005, Des Plaines, Illinois, United States
- Site US-007, Glenview, Illinois, United States
- Site US-020, Gurnee, Illinois, United States
- Site US-008, Baton Rouge, Louisiana, United States
- Site US-011, Mandeville, Louisiana, United States
- Site US-010, Tupelo, Mississippi, United States
- Site US-006, St Louis, Missouri, United States
- Site US-014, Clifton, New Jersey, United States
- Site US-002, Albany, New York, United States
- Site US-016, Rochester, New York, United States
- Site US-025, Brunswick, Ohio, United States
- Site US-023, Dayton, Ohio, United States
- Site US-027, Westlake, Ohio, United States
- Site US-019, Providence, Rhode Island, United States
- Site US-003, Cordova, Tennessee, United States
Other microbiome trials you might be interested in
Recurrent C. Difficile (rCDI)Ulcerative Colitis (UC)Metabolic Syndrome (MetS)
The gut microbiota plays a key role in immunity and metabolism and contributes to diseases such as recurrent C. difficil…
Rome, ItalyEst. completion Jan 19, 2029
Crohn's DiseaseUlcerative Colitis (UC)Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)
Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online p…
Los Angeles, United StatesEst. completion Jul 2027
Site US-024, Garland, Texas, United StatesSite US-009, Georgetown, Texas, United StatesSite US-030, Houston, Texas, United StatesSite US-015, Lubbock, Texas, United StatesSite US-017, Mansfield, Texas, United StatesSite US-001, Southlake, Texas, United StatesSite US-004, Tyler, Texas, United StatesSite US-013, Richmond, Virginia, United StatesSite US-021, Bellevue, Washington, United StatesSite US-029, Tacoma, Washington, United StatesSite US-012, Milwaukee, Wisconsin, United StatesSite CA-005, Calgary, Alberta, CanadaSite CA-004, Edmonton, Alberta, CanadaSite CA-006, Greater Sudbury, Ontario, CanadaSite CA-003, London, Ontario, CanadaSite CA-002, Scarborough Village, Ontario, CanadaSite CA-007, Montreal, Quebec, CanadaSite CA-001, Montreal, Quebec, CanadaSite CZ-005, Brno, CzechiaSite CZ-002, Brno, CzechiaSite CZ-008, Havířov, CzechiaSite CZ-006, Hradec Králové, CzechiaSite CZ-007, Prague, CzechiaSite CZ-004, Slaný, CzechiaSite FR-003, Amiens, FranceSite FR-005, Clermont-Ferrand, FranceSite FR-002, Neuilly-sur-Seine, FranceSite FR-001, Nice, FranceSite FR-004, Saint-Priest-en-Jarez, FranceSite GE-003, Batumi, Quebec, GeorgiaSite GE-007, Tbilisi, Quebec, GeorgiaSite GE-002, Tbilisi, Quebec, GeorgiaSite GE-004, Tbilisi, Quebec, GeorgiaSite GE-008, Tbilisi, Quebec, GeorgiaSite GE-001, Tbilisi, Quebec, GeorgiaSite GE-005, Tbilisi, Quebec, GeorgiaSite GE-006, Tbilisi, Quebec, GeorgiaSite HU-005, Budapest, HungarySite HU-002, Budapest, HungarySite HU-001, Budapest, HungarySite HU-004, Debrecen, HungarySite HU-007, Gyöngyös, HungarySite HU-006, Tatabánya, HungarySite HU-003, Veszprém, HungarySite IT-002, Bari, ItalySite IT-004, Bologna, ItalySite IT-007, Matera, ItalySite IT-009, Negrar, ItalySite IT-001, Rome, ItalySite IT-003, Rome, ItalySite IT-008, Rome, ItalySite IT-006, Rozzano, ItalySite IT-005, San Giovanni Rotondo, ItalySite IT-010, Turin, ItalySite LV-003, Liepāja, LatviaSite LV-002, Riga, LatviaSite LV-001, Riga, LatviaSite PL-014, Bydgoszcz, PolandSite PL-005, Elblag, PolandSite PL-006, Katowice, PolandSite PL-022, Kielce, PolandSite PL-002, Krakow, PolandSite PL-016, Krakow, PolandSite PL-020, Kłodzko, PolandSite PL-021, Lodz, PolandSite PL-004, Lublin, PolandSite PL-008, Nowy Targ, PolandSite PL-018, Opole, PolandSite PL-003, Poznan, PolandSite PL-010, Sopot, PolandSite PL-012, Staszów, PolandSite PL-001, Szczecin, PolandSite PL-015, Szczecin, PolandSite PL-007, Torun, PolandSite PL-019, Tychy, PolandSite PL-017, Warsaw, PolandSite PL-013, Warsaw, PolandSite PL-009, Wroclaw, PolandSite PL-011, Wroclaw, PolandSite RO-001, Bucharest, RomaniaSite RO-003, Bucharest, RomaniaSite RO-006, Constanța, RomaniaSite RO-004, Ploieşti, RomaniaSite RO-002, Timișoara, RomaniaSite RO-005, Timișoara, RomaniaSite RS-006, Belgrade, SerbiaSite RS-001, Belgrade, SerbiaSite RS-002, Belgrade, SerbiaSite RS-004, Leskovac, SerbiaSite RS-005, Užice, SerbiaSite RS-003, Zrenjanin, SerbiaSite SK-001, Banská Bystrica, SlovakiaSite SK-004, Košice, SlovakiaSite SK-002, Prešov, SlovakiaSite SK-005, Prešov, SlovakiaSite SK-006, Zvolen, SlovakiaUlcerative Colitis (Disorder)
This multicenter longitudinal observational cohort study aims to characterize objective disease-control trajectories, tr…
Multiple LocationsEst. completion Dec 30, 2031